[go: up one dir, main page]

WO2012078519A3 - 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 - Google Patents

3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 Download PDF

Info

Publication number
WO2012078519A3
WO2012078519A3 PCT/US2011/063312 US2011063312W WO2012078519A3 WO 2012078519 A3 WO2012078519 A3 WO 2012078519A3 US 2011063312 W US2011063312 W US 2011063312W WO 2012078519 A3 WO2012078519 A3 WO 2012078519A3
Authority
WO
WIPO (PCT)
Prior art keywords
transglutaminase
acylidene
inhibition
derivatives
oxoindole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/063312
Other languages
French (fr)
Other versions
WO2012078519A2 (en
Inventor
John Griffin
Brian Raimundo
Peter Madrid
Chaitan Khosla
Xi JIN
Cornelius Kloeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numerate Inc
Leland Stanford Junior University
Original Assignee
Numerate Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numerate Inc, Leland Stanford Junior University filed Critical Numerate Inc
Publication of WO2012078519A2 publication Critical patent/WO2012078519A2/en
Publication of WO2012078519A3 publication Critical patent/WO2012078519A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are acylidene oxoindole derivatives, compositions including them, and methods of inhibiting transglutaminase 2 and treating diseases mediated by transglutaminase 2 by administering such derivatives and compositions.
PCT/US2011/063312 2010-12-06 2011-12-05 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 Ceased WO2012078519A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42021610P 2010-12-06 2010-12-06
US61/420,216 2010-12-06

Publications (2)

Publication Number Publication Date
WO2012078519A2 WO2012078519A2 (en) 2012-06-14
WO2012078519A3 true WO2012078519A3 (en) 2012-08-02

Family

ID=46207668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/063312 Ceased WO2012078519A2 (en) 2010-12-06 2011-12-05 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2

Country Status (1)

Country Link
WO (1) WO2012078519A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6130491B2 (en) 2012-04-12 2017-05-17 ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ Methods and compositions for treating Ewing sarcoma family tumors
AU2015328121B2 (en) 2014-10-09 2019-11-21 Oncternal Therapeutics, Inc. Indolinone compounds and uses thereof
CN104496885B (en) * 2015-01-12 2017-08-25 中国药科大学 A kind of preparation method of the Nitroisatoic of 4 amino of N methyl 5
US9822122B2 (en) 2016-03-31 2017-11-21 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
JP6885629B2 (en) 2016-07-29 2021-06-16 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Use of indolinone compounds
TWI825144B (en) * 2018-08-10 2023-12-11 美商思達利醫藥公司 Transglutaminase 2 (tg2) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056769A2 (en) * 2002-12-20 2004-07-08 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
US20060052308A1 (en) * 2003-11-18 2006-03-09 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
WO2009123080A1 (en) * 2008-04-01 2009-10-08 アステラス製薬株式会社 Indolinone compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056769A2 (en) * 2002-12-20 2004-07-08 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
US20060052308A1 (en) * 2003-11-18 2006-03-09 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
WO2009123080A1 (en) * 2008-04-01 2009-10-08 アステラス製薬株式会社 Indolinone compound

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASSABDRA L. WOODARD ET AL.: "Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 18, 2003, pages 3877 - 3883 *
CORNELIUS KLOECK ET AL.: "Acylideneoxoindoles: A new class of reversible inhibitors of human transglutaminase 2", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, vol. 21, no. 9, 16 December 2010 (2010-12-16), pages 2692 - 2696, XP002751380, DOI: doi:10.1016/J.BMCL.2010.12.037 *
LINDSEY J. MACPHERSON ET AL.: "Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines", NATURE, vol. 445, 2007, pages 541 - 545, XP009149873, DOI: doi:10.1038/nature05544 *
STANLEY REHN ET AL.: "The reaction between 3-aminocrotonates and oxindole- 3-ylidene derivatives: synthesis of highly substituted pyrroles", TETRAHEDRON, vol. 61, no. 12, 2005, pages 3115 - 3123 *

Also Published As

Publication number Publication date
WO2012078519A2 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
IN2014CN04907A (en)
PH12012501589A1 (en) Macrocycles as factor xia inhibitors
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
IN2012DN00971A (en)
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
WO2013192049A3 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
WO2011028044A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
HK1205506A1 (en) Protein kinase inhibitors
WO2011028043A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
WO2011119777A3 (en) Compositions and methods for treatment of neurodegenerative disease
IN2015DN01151A (en)
AU2011326186A8 (en) Selective glycosidase inhibitors and uses thereof
SG195257A1 (en) Anti-thrombotic compounds
HK1208221A1 (en) Nampt inhibitors
MY164354A (en) Asymmetric ureas and medical uses thereof
MX2012001134A (en) Compositions and methods for inhibition of the jak pathway.
MX363551B (en) Pyrazine kinase inhibitors.
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
MX370253B (en) Compositions of jasmonate compounds and methods of use.
WO2013040227A3 (en) Therapeutic compounds
WO2011126842A3 (en) Targeting micrornas for the treatment of cardiac disorders
WO2012078519A3 (en) 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11846904

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11846904

Country of ref document: EP

Kind code of ref document: A2